tbuckley/cabot-search huggingface dataset:
An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk
Authors: Catherine Diefenbach, Sarit Assouline, Francesc Bosch, Chan Y. Cheah, Won Seog Kim, Matthew J Matasar, Carlos Panizo, Dok Hyun Yoon, Brendan Bender, Genevive Hernandez, Chi-Chung Li, Bruce McCall, Carol O'Hear, Michael C Wei, Shen Yin, Kasra Yousefi, Antonia Kwan, Loretta J. Nastoupil
Journal: Blood (2019)
In vivo delivery of synthetic DNA–encoded antibodies induces broad HIV-1–neutralizing activity
Authors: Megan C. Wise, Ziyang Xu, Edgar Tello-Ruiz, Charles Beck, Aspen Trautz, Ami Patel, Sarah T.C. Elliott, Neethu Chokkalingam, Sophie Kim, Melissa G. Kerkau, Kar Muthumani, Jingjing Jiang, Paul D. Fisher, Stephany J. Ramos, Trevor R.F. Smith, Janess Mendoza, Kate E. Broderick, David C. Montefiori, Guido Ferrari, Daniel W. Kulp, Laurent M. Humeau, David B. Weiner
Journal: Journal of Clinical Investigation (2019)

Interventions to prevent HIV-1 infection and alternative tools in HIV cure therapy remain pressing goals. Recently, numerous broadly neutralizing HIV-1 monoclonal antibodies (bNAbs) have been developed that possess the characteristics necessary for potential prophylactic or therapeutic approaches. However, formulation complexities, especially for multiantibody deliveries, long infusion times, and production issues could limit the use of these bNAbs when deployed, globally affecting their potential application. Here, we describe an approach utilizing synthetic DNA-encoded monoclonal antibodies (dmAbs) for direct in vivo production of prespecified neutralizing activity. We designed 16 different bNAbs as dmAb cassettes and studied their activity in small and large animals. Sera from animals administered dmAbs neutralized multiple HIV-1 isolates with activity similar to that of their parental recombinant mAbs. Delivery of multiple dmAbs to a single animal led to increased neutralization breadth. Two dmAbs, PGDM1400 and PGT121, were advanced into nonhuman primates for study. High peak-circulating levels (between 6 and 34 μg/ml) of these dmAbs were measured, and the sera of all animals displayed broad neutralizing activity. The dmAb approach provides an important local delivery platform for the in vivo generation of HIV-1 bNAbs and for other infectious disease antibodies.
Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family
Authors: Thomas W. LeBlanc, Roland B. Walter, Loriana Hernandez-Aldama, Kate Sully, Timothy J Bell, Chloe Johnson, Francois Peloquin, Adam Gater, Verna L Welch, Louise O'Hara, Ryan Hohman, Diana Merino, Nigel H. Russell, Neil Horikoshi, Dawn Maze
Journal: Blood (2019)
ATIM-06. TREATMENT OF RECURRENT/REFRACTORY (R/R) ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE 3) PATIENTS WITH ANTI-TGFß2 RNA THERAPEUTIC OT-101 VERSUS TEMOZOLOMIDE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL
Authors: Fatih Uckun, Sanjive Qazi, David Nam, Larn Hwang, Vuong Trieu
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND OT-101 is a first-in-class RNA therapeutic designed to disrupt the immunosuppressive action of TGFß2. During Phase 1 clinical trials, OT-101 induced partial responses in R/R AA patients. We now report our clinical results from a randomized Phase IIB study (NCT00431561) that further evaluated its single agent activity in R/R AA patients in side-by-side comparison with the standard chemotherapy drug temozolomide (TMZ). METHODS OT-101 was administered via high-flow microperfusion with an intratumoral catheter using a convection enhanced delivery (CED) system. 26 AA patients (12: 2.5 mg/cycle; 14: 19.8 mg/cycle) received 7-day cycles of OT-101 every other week via continuous infusion for 4–11 cycles. Response determinations were based on central review of MRI scans by an independent review committee according to standard as well as modified McDonald criteria. 11 patients in the active control arm were treated with TMZ (150–200 mg/m2, 5 days/28-day cycles x up to 6 treatment cycles). Standard statistical methods were applied for the analysis of data. RESULTS 14 of 26 patients (53.8%) treated with 4–11 cycles of OT-101 had either a CR (N=2) or PR (N=12) as their best overall response. The average time until 99% reduction of their tumor volumes ranged from 9.9 to 115.4 (median: 23.7) months. In contrast, only 1 of 10 evaluable patients (10%) treated with TMZ achieved an objective response which was a PR (Fisher’s exact test, 2-tailed, P-value = 0.0002). The median overall survival (OS) was 1154 days (95% CI: 811 - &gt;1743) for the OT-101 group and 590 days (95% CI: 287 - &gt;1137) days for the TMZ group (Log Rank Chi Square = 7.55, P-value = 0.006). CONCLUSION Our results confirm and extend previous studies and provide early evidence that the anti-TGFß2 RNA therapeutic OT-101 is at least as active as TMZ in salvage therapy of R/R AA patients.
The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial
Authors: Charles Craddock, Aimee E Jackson, Ram K Malladi, Maria H Gilleece, Andy Peniket, Rahuman Salim, Eleni Tholouli, Victoria Potter, Charles R Crawley, Rachel Elizabeth Protheroe, Anne Parker, Keith Wilson, Jiri Pavlu, Sandeep Nagra, Shamyla Siddique, Andrea Hodgkinson, John Mason, Keith Wheatley, Nigel H. Russell, Sylvie D. Freeman
Journal: Blood (2019)
EXTH-70. ENHANCEMENT OF ANTITUMOR ACTIVITY BY USING 5-ALA–MEDIATED SONODYNAMIC THERAPY TO INDUCE APOPTOSIS AND NECROSIS IN A MOUSE GLIOMA MODEL
Authors: Satoshi Suehiro, Takanori Ohnishi, Akihiro Inoue, Daisuke Yamashita, Masahiro Nishikawa, Shiro Ohue, Takeharu Kunieda
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE High invasiveness of malignant gliomas frequently causes local tumor recurrence. To control such recurrence, novel therapies targeted toward infiltrating glioma cells are required. Here, we examined cytotoxic effects of sonodynamic therapy (SDT) combined with a sonosensitizer, 5-aminolevulinic acid (5-ALA), on malignant gliomas both in vitro and in vivo. METHODS In vitro cytotoxicity of 5-ALA-SDT was evaluated in U87 and U251 glioma cells and in U251Oct-3/4 glioma stemlike cells. Treatment-related apoptosis was analyzed using flow cytometry. Intracellular reactive oxygen species (ROS) were measured and the role of ROS in treatment-related cytotoxicity was examined. Effects of 5-ALA-SDT with high-intensity focused ultrasound (HIFU) on tumor growth, survival of glioma-transplanted mice, and histological features of the mouse brains were investigated. RESULTS The 5-ALA-SDT inhibited cell growth and changed cell morphology. Flow cytometric analysis indicated that 5-ALA-SDT induced apoptotic cell death. The 5-ALA-SDT generated higher ROS than in the control group, and inhibition of ROS generation completely eliminated the cytotoxic effects of 5-ALA-SDT. In the in vivo study, 5-ALA-SDT with HIFU greatly prolonged survival of the tumor-bearing mice compared with that of the control group (p &lt; 0.05). Histologically, 5-ALA-SDT produced mainly necrosis of the tumor tissue in the focus area and induced apoptosis of the tumor cells in the perifocus area around the target of the HIFU-irradiated field. Normal brain tissues around the ultrasonic irradiation field of HIFU remained intact. CONCLUSIONS The 5-ALA-SDT was cytotoxic toward malignant gliomas. Generation of ROS by the SDT was thought to promote apoptosis of glioma cells. The 5-ALA-SDT with HIFU induced tumor necrosis in the focus area and apoptosis in the perifocus area of the HIFU-irradiated field. These results suggest that 5-ALA-SDT with HIFU may present a less invasive and tumor-specific therapy, not only for a tumor mass but also for infiltrating tumor cells in malignant gliomas.
A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models
Authors: Anna Bunin, Katy McGrath, Ann Marie Rossi, Matthew Welsch, Christian Vidal, David Trinh, David Spiegel, Luca Rastelli, Enrique Alvarez
Journal: Blood (2019)
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Authors: Adam D. Cohen, Noopur Raje, Jessica A. Fowler, Khalid Mezzi, Emma C. Scott, Madhav V. Dhodapkar
Journal: Clinical Cancer Research (2019)

The progression of multiple myeloma, a hematologic malignancy characterized by unregulated plasma cell growth, is associated with increasing innate and adaptive immune system dysfunction, notably in the T-cell repertoire. Although treatment advances in multiple myeloma have led to deeper and more durable clinical responses, the disease remains incurable for most patients. Therapeutic strategies aimed at overcoming the immunosuppressive tumor microenvironment and activating the host immune system have recently shown promise in multiple myeloma, particularly in the relapsed and/or refractory disease setting. As the efficacy of T-cell-dependent immuno-oncology therapy is likely affected by the health of the endogenous T-cell repertoire, these therapies may also provide benefit in alternate treatment settings (e.g., precursor disease; after stem cell transplantation). This review describes T-cell-associated changes during the evolution of multiple myeloma and provides an overview of T-cell-dependent immuno-oncology approaches under investigation. Vaccine and checkpoint inhibitor interventions are being explored across the multiple myeloma disease continuum; treatment modalities that redirect patient T cells to elicit an anti-multiple myeloma response, namely, chimeric antigen receptor (CAR) T cells and bispecific antibodies [including BiTE (bispecific T-cell engager) molecules], have been primarily evaluated to date in the relapsed and/or refractory disease setting. CAR T cells and bispecific antibodies/antibody constructs directed against B-cell maturation antigen have generated excitement, with clinical data demonstrating deep responses. An increased understanding of the complex interplay between the immune system and multiple myeloma throughout the disease course will aid in maximizing the potential for T-cell-dependent immuno-oncology strategies in multiple myeloma.
<scp>GRK</scp>5 Inhibition Attenuates Cartilage Degradation via Decreased <scp>NF</scp>‐κB Signaling
Authors: Takuya Sueishi, Yukio Akasaki, Norio Goto, Ichiro Kurakazu, Masakazu Toya, Masanari Kuwahara, Taisuke Uchida, Mitsumasa Hayashida, Hidetoshi Tsushima, Hirofumi Bekki, Martin K. Lotz, Yasuharu Nakashima
Journal: Arthritis & Rheumatology (2019)

NF-κB-dependent signaling is an important modulator in osteoarthritis (OA), and G protein-coupled receptor kinase 5 (GRK5) regulates the NF-κB pathway. This study was undertaken to investigate the functional involvement of GRK5 in OA pathogenesis.GRK5 expression in normal and OA human knee joints was analyzed immunohistochemically. Gain- or loss-of-function experiments were performed using human and mouse chondrocytes. OA was induced in GRK5-knockout mice by destabilization of the medial meniscus, and histologic examination was performed. OA was also induced in wild-type mice, which were then treated with an intraarticular injection of amlexanox, a selective GRK5 inhibitor, every 5 days for 8 weeks.GRK5 protein expression was increased in human OA cartilage. In vitro, expression levels of OA-related factors and NF-κB transcriptional activation were down-regulated by suppression of the GRK5 gene in human OA chondrocytes (3.49-fold decrease in IL6 [P < 0.01], 2.43-fold decrease in MMP13 [P < 0.01], and 2.66-fold decrease in ADAMTS4 [P < 0.01]). Conversely, GRK5 overexpression significantly increased the expression of OA-related catabolic mediators and NF-κB transcriptional activation. On Western blot analysis, GRK5 deletion reduced IκBα phosphorylation (up to 4.4-fold decrease [P < 0.05]) and decreased p65 nuclear translocation (up to 6.4-fold decrease [P < 0.01]) in mouse chondrocytes. In vivo, both GRK5 deletion and intraarticular amlexanox protected mouse cartilage against OA.Our results suggest that GRK5 regulates cartilage degradation through a catabolic response mediated by NF-κB signaling, and is a potential target for OA treatment. Furthermore, amlexanox may be a major compound in relevant drugs.
Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
Authors: Caitlin R. Rausch, Courtney D. DiNardo, Abhishek Maiti, Nadya Jammal, Tapan M. Kadia, Kayleigh Marx, Gautam M. Borthakur, J Michael Savoy, Naveen Pemmaraju, Adam Dipippo, Naval G. Daver, Serena Chew, Koji Sasaki, Ghayas C. Issa, Kiran Naqvi, Farhad Ravandi, Hagop M. Kantarjian, Marina Y Konopleva
Journal: Blood (2019)
Response to Comment on: Hernandez et al. Patterns of Glycemia in Normal Pregnancy: Should the Current Therapeutic Targets Be Challenged? Diabetes Care 2011;34:1660–1668
Authors: Teri L. Hernandez, Jacob E. Friedman, Rachael E. Van Pelt, Linda A. Barbour
Journal: Diabetes Care (2011)

We appreciate Ryan's (1) thoughtful comments. The intent of our pooled analysis was to describe a normal pattern of glycemia in nonobese pregnant women according to the published data (2). We demonstrated that, similar to the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study (3), glucose concentrations in normal pregnancy are lower than were previously appreciated. If the treatment goal for pregnancies affected by diabetes is to mimic patterns of glycemia in normal pregnancy, then a contemporary understanding of normo- or euglycemia is warranted. On the basis of our review, we suggested that prospective trials test whether 1- and 2-h postprandial (PP) targets of <122 and <110 mg/dL can attenuate incidence of fetal macrosomia and large-for-gestational-age (LGA) …
Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma
Authors: Carolina Terragna, Andrea Poletti, Vincenza Solli, Marina Martello, Enrica Borsi, Lucia Pantani, Agboyi Lakpo, Luca Cifarelli, Silvia Armuzzi, Rosalinda Termini, Elena Zamagni, Paola Tacchetti, Serena Rocchi, Katia Mancuso, Serena Rocchi, Ilaria Rizzello, Giulia Marzocchi, Nicoletta Testoni, Luca Dozza, Maria Teresa Petrucci, Anna Marina Liberati, Giuseppe Rossi, Mario Boccadoro, Michele Cavo
Journal: Blood (2019)
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX
Authors: Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Juan Shen, Tymara Berry, Carrie Brownstein, Ruben A Mesa
Journal: Blood (2019)
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis
Authors: Xintong Li, Kathleen M Andersen, Hsien-Yen Chang, Jeffrey R Curtis, G Caleb Alexander
Journal: Annals of the Rheumatic Diseases (2019)

To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.
Expression and Function of B7.2 and B7-H2 Molecules on Myeloma Cells
Authors: Taishi Yamashita, Hideto Tamura, Chikako Sato, Asaka Kondo, Eiji Shinya, Hidemi Takahashi, Lieping Chen, Takashi Tsuji, Kazuo Dan, Kiyoyuki Ogata
Journal: Blood (2008)
Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis
Authors: Fredrik H. Schjesvold, Paul G. Richardson, Michel Attal, Thierry Facon, Adrián Alegre, Andrew Spencer, Artur Jurczyszyn, Kazutaka Sunami, Laurent Frenzel, Chang-Ki Min, Solenn Le-Guennec, Frank Campana, Helgi van de Velde, Samira Bensfia, Sara Bringhen
Journal: Blood (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Authors: Richard A Furie, Eric F Morand, Ian N Bruce, Susan Manzi, Kenneth C Kalunian, Edward M Vital, Theresa Lawrence Ford, Ramesh Gupta, Falk Hiepe, Mittermayer Santiago, Philip Z Brohawn, Anna Berglind, Raj Tummala
Journal: The Lancet Rheumatology (2019)
Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience
Authors: Michela Ansuinelli, Antonella Vitale, Giovanna Pecoraro, Saveria Capria, Silvia Maria Trisolini, Clara Minotti, Claudio Cartoni, Anna Maria Testi, Maria Luisa Moleti, Anna Paola Iori, Walter Barberi, Irene Della Starza, Loredana Elia, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, Sabina Chiaretti, Robin Foà
Journal: Blood (2019)
EXTH-16. HUMAN PLACENTAL HEMATOPOIETIC STEM CELL DERIVED NATURAL KILLER CELLS FOR GLIOBLASTOMA IMMUNOTHERAPY
Authors: Shuyang He, Joseph Gleason, Nassir Habboubi, Robert Hariri, Xiaokui Zhang
Journal: Neuro-Oncology (2019)

Abstract Taniraleucel (CYNK-001) is an allogeneic, off-the-shelf cell therapy enriched for CD56+/CD3- NK cells expanded from placental CD34+ cells. CYNK-001 exhibits in vitro cytotoxicity against various cancer cell types, including glioblastoma multiforme (GBM), and secretes cytokines during co-culture with cancer cells. To evaluate in vivo anti-GBM activity, safety and persistence of CYNK-001, we conducted two studies in the non-obese diabetic (NOD)-scid IL2Rgammanull (NSG) immune deficient mouse models. First, CYNK-001 in vivo anti-GBM activity was assessed in a U-87MG orthotopic NSG mouse model. Luciferase-expressing U-87MG cells were stereotactically injected into the cranium of NSG mice at Day 0. Repeated dosing of 0.5x106 CYNK-001 cells at Day 14 and Day 25 by intracranial (IC) injection showed a statistically significant reduction of Bioluminescence Imaging (BLI) compared to the PBS control. Furthermore, intravenous (IV) and intracerebroventricular (ICV) routes of administration were evaluated compared to IC. CYNK-001 administered with IC resulted in a greater reduction of BLI than IV and ICV. Second, a single-dose toxicity study was conducted in naïve NSG mice to assess the safety and persistence of CYNK-001 following an IC injection. IC administration of 1×106 CYNK-001 was well tolerated, and no adverse clinical symptoms were observed. Quantitative polymerase chain reaction (qPCR) analysis for the human telomerase reverse transcriptase (hTERT) gene revealed that CYNK-001 persisted in the brain up to seven days. Our studies demonstrated that CYNK-001with IC administration appears safe and well tolerated in naïve as well as U-87MG tumor bearing NSG mice. Furthermore, CYNK-001 anti-tumor activity was exhibited in a GBM orthotopic NSG mouse model. Taken together, our data support a safety and efficacy evaluation of CYNK-001 in patients with GBM. A Phase 1 study in adult patients with recurrent/refractory GBM is planned to start this year evaluating the safety and efficacy of CYNK-001 with both IV and IC administrations.
Near-Infrared Spectroscopy to Monitor Nutritional Status of Neonates: A Review
Authors: Alexander P. Miller, Fatin Hamimi Mustafa, Peter W. Jones, Heather E. Jeffery, Angela E. Carberry, Alistair L. McEwan
Journal: IEEE Reviews in Biomedical Engineering (2019)

The World Health Organization reported that half or more of all under five deaths were caused by under-nutrition in developing countries, with the majority of these deaths occurring in the first week of life. Even if the under-nourished neonates manage to survive, they are exposed to long-term health impacts, including obesity, cardiovascular disease, and hypertension. Along with those health-impacts they can be exposed to risks related to detrimental early development, such as physical impairment, stunting, brain dysfunction, and reduced cognitive development. Body fat percentage has been recognized to be closely associated with under-nutrition in neonates. In this article, the potential of near infrared spectroscopy (NIRS), along with previous methods to measure body fat in neonates, is reviewed and discussed.
NIMG-70. A LABEL-FREE APPROACH TO ASSESS CHEMOTHERAPY DRUG CONCENTRATION USING CHEMICAL EXCHANGE SATURATION TRANSFER MRI – A FEASIBILITY STUDY
Authors: David Kamson, Stuart Grossman, Zheng Han, Xiang Xu, Peter van Zijl, Guanshu Liu
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Drug delivery is one of the most pressing problems in neuro-oncology as the blood-brain barrier (BBB) uniquely limits penetration of substances into the brain parenchyma. Plasma and CSF drug concentrations are relatively easy to measure, but do not necessarily reflect concentrations in the brain. Furthermore, invasive measurements may be inaccurate in regions of heterogeneous BBB integrity. Advanced non-invasive imaging approaches may help bridge this information gap without the added risk. Chemical exchange saturation transfer (CEST) is an MRI technique that allows in vivo detection of molecules with a suitable hydrogen exchange rate, such as methotrexate (MTX). High-dose MTX is commonly used in oncology and its concentrations in urine (&gt;2000µM), plasma (&gt;1000µM) and enhancing brain tumors (&gt;350µM) are well above the theoretical threshold of CEST. AIM: We aimed to confirm the CEST detectability of MTX in vitro, and to estimate the currently lowest measurable concentrations in solutions mimicking bodily fluids. METHODS We used a 9.4T MRI to assess the spectra of MTX at 37°C at various concentrations (0.1–10.0 mM) in a phosphate-buffered saline (PBS) solution at various pH (6.0–8.0), as well as in synthetic urine at pH 6.2. RESULTS CEST signals attributable to MTX at 1.5 and 2.7ppm were successfully detected in PBS at concentrations as low as 500µM. The optimal field strength was 3.6µT. While increasing pH increased the detection threshold of the 2.7ppm signal, the 1.5ppm signal was minimally affected by pH within physiologic ranges. In synthetic urine, the MTX CEST signal was well-detectable even at concentrations as low as 200µM. CONCLUSIONS These preliminary results suggest that MTX-CEST may be feasible at field strengths achievable in clinical scanners and at MTX concentrations previously measured in enhancing brain tumors treated with high-dose MTX. Further optimization of the technique for in human use is under way.
Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?
Authors: Lucrecia Yanez San Segundo, Noemi Fernandez Escalada, Arancha Bermúdez, Guillermo Martín Sánchez, Sara García Avila, Mónica López Duarte, Mercedes Colorado, Iñigo Romon, Carlos Richard, Enrique M. Ocio
Journal: Blood (2019)
Heme-Regulated Inhibitor (HRI) Depletion Cooperates with Pharmacologic Inducers to Strongly Elevate Fetal Hemoglobin and Reduce Sickle Cell Formation
Authors: Scott A. Peslak, Xianjiang Lan, Eugene Khandros, Peng Huang, Jennifer A. Yano, Jeremy D. Grevet, Osheiza Abdulmalik, Cheryl A Keller, Ross C. Hardison, Junwei Shi, Gerd A. Blobel
Journal: Blood (2019)